BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11807153)

  • 1. Empirical antifungal therapy--new options, new tradeoffs.
    Marr KA
    N Engl J Med; 2002 Jan; 346(4):278-80. PubMed ID: 11807153
    [No Abstract]   [Full Text] [Related]  

  • 2. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
    Ullmann AJ; Heussel CP; Cornely OA
    N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041526
    [No Abstract]   [Full Text] [Related]  

  • 3. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever.
    Powers JH; Dixon CA; Goldberger MJ
    N Engl J Med; 2002 Jan; 346(4):289-90. PubMed ID: 11807157
    [No Abstract]   [Full Text] [Related]  

  • 4. Decisions about voriconazole versus liposomal amphotericin B.
    Walsh TJ; Lee J; Dismukes WE
    N Engl J Med; 2002 May; 346(19):1499; author reply 1499. PubMed ID: 12000825
    [No Abstract]   [Full Text] [Related]  

  • 5. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
    Apisarnthanarak A; Little JR; Tebas P
    N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041527
    [No Abstract]   [Full Text] [Related]  

  • 6. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
    Johnson JR
    N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12037157
    [No Abstract]   [Full Text] [Related]  

  • 7. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
    Walsh TJ; Pappas P; Winston DJ; Lazarus HM; Petersen F; Raffalli J; Yanovich S; Stiff P; Greenberg R; Donowitz G; Schuster M; Reboli A; Wingard J; Arndt C; Reinhardt J; Hadley S; Finberg R; Laverdière M; Perfect J; Garber G; Fioritoni G; Anaissie E; Lee J;
    N Engl J Med; 2002 Jan; 346(4):225-34. PubMed ID: 11807146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal therapy in patients with fever and neutropenia--more rational and less empirical?
    Klastersky J
    N Engl J Med; 2004 Sep; 351(14):1445-7. PubMed ID: 15459307
    [No Abstract]   [Full Text] [Related]  

  • 9. Treating disseminated fusariosis: amphotericin B, voriconazole or both?
    Ho DY; Lee JD; Rosso F; Montoya JG
    Mycoses; 2007 May; 50(3):227-31. PubMed ID: 17472622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful management of invasive aspergillosis with voriconazole and amphoteracin B therapy in a patient with acute mycloid leukemia (AML-M2).
    Manzoor NF; Azim S; Fadoo Z
    J Pak Med Assoc; 2010 Nov; 60(11):977-9. PubMed ID: 21375212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
    Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
    Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The future of antifungal agents].
    Maesaki S
    Rinsho Ketsueki; 2007 Jan; 48(1):26-35. PubMed ID: 17313074
    [No Abstract]   [Full Text] [Related]  

  • 13. Empirical antifungal therapy for persistent fever in patients with neutropenia.
    Chandrasekar PH
    Clin Infect Dis; 2001 Jan; 32(2):320-1. PubMed ID: 11170928
    [No Abstract]   [Full Text] [Related]  

  • 14. Review: voriconazole for prevention or treatment of invasive fungal infections in cancer with neutropenia.
    Morris AM
    Ann Intern Med; 2014 Jul; 161(2):JC8. PubMed ID: 25023274
    [No Abstract]   [Full Text] [Related]  

  • 15. Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient.
    Consigny S; Dhedin N; Datry A; Choquet S; Leblond V; Chosidow O
    Clin Infect Dis; 2003 Jul; 37(2):311-3. PubMed ID: 12856225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
    N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia.
    Frothingham R
    Clin Infect Dis; 2002 Oct; 35(7):896-7; author reply 897-8. PubMed ID: 12228830
    [No Abstract]   [Full Text] [Related]  

  • 18. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Tattevin P; Bareau B; Camus C
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675091
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
    Przepiorka D; Buadi FK; McClune B
    Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia.
    Al-Badriyeh D; Liew D; Stewart K; Kong DC
    J Antimicrob Chemother; 2009 Jan; 63(1):197-208. PubMed ID: 19001450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.